ABBV-295
ABBV295 · AbbVie / Gubra
Investigational long-acting amylin analogue in a Phase 2 dose-finding study.
Results availability
Phase 2 initiated; numerical Phase 2 results pending.
Mechanism at a glance
Obesity stage by formulation
Latest: Phase 2 NCT07752979 initiated in August 2026; approximately 360 participants planned.
Next: Week-32 primary weight endpoint; 52-week treatment period. Phase 2 efficacy results pending.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 2 studies1 record
ABBV-295 Phase 2 dose-finding
Weight managementApproximately 360 adults with obesity or overweight plus a weight-related comorbidity; randomized, double-blind, placebo-controlled; six active treatment arms and placebo. Treatment 52 weeks; primary weight endpoint at week 32.
Related reading: ABBV-295 in the EASD 2026 review ↗
